[go: up one dir, main page]

ITTO20110636A1 - Composizione farmaceutica e metodo per inibire la produzione o amplificare l'eliminazione della proteina p24 - Google Patents

Composizione farmaceutica e metodo per inibire la produzione o amplificare l'eliminazione della proteina p24

Info

Publication number
ITTO20110636A1
ITTO20110636A1 IT000636A ITTO20110636A ITTO20110636A1 IT TO20110636 A1 ITTO20110636 A1 IT TO20110636A1 IT 000636 A IT000636 A IT 000636A IT TO20110636 A ITTO20110636 A IT TO20110636A IT TO20110636 A1 ITTO20110636 A1 IT TO20110636A1
Authority
IT
Italy
Prior art keywords
elimination
pharmaceutical composition
propine
amplify
inhibiting production
Prior art date
Application number
IT000636A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Sergey Alexandrovich Tarasov
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of ITTO20110636A1 publication Critical patent/ITTO20110636A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT000636A 2010-08-06 2011-07-15 Composizione farmaceutica e metodo per inibire la produzione o amplificare l'eliminazione della proteina p24 ITTO20110636A1 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133046/15A RU2517084C2 (ru) 2010-08-06 2010-08-06 Способ и средство для ингибирования продукции или усиления элиминации белка р24

Publications (1)

Publication Number Publication Date
ITTO20110636A1 true ITTO20110636A1 (it) 2012-02-07

Family

ID=44899160

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000636A ITTO20110636A1 (it) 2010-08-06 2011-07-15 Composizione farmaceutica e metodo per inibire la produzione o amplificare l'eliminazione della proteina p24

Country Status (16)

Country Link
US (2) US20120263726A1 (it)
JP (1) JP2013535483A (it)
CN (1) CN103179987A (it)
AU (1) AU2011287286A1 (it)
CA (1) CA2807523A1 (it)
DE (1) DE112011102639T5 (it)
EA (1) EA029791B1 (it)
ES (1) ES2415029R1 (it)
GB (1) GB2496356A (it)
IT (1) ITTO20110636A1 (it)
MX (1) MX2013001450A (it)
PH (1) PH12013500233A1 (it)
RU (1) RU2517084C2 (it)
SG (1) SG187735A1 (it)
UA (1) UA112752C2 (it)
WO (1) WO2012017322A2 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
ES2440393R1 (es) 2010-07-15 2014-10-10 Oleg Iliich Epshtein Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo
AU2011287288A1 (en) 2010-07-15 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
AU2011281244A1 (en) 2010-07-21 2013-03-07 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2603623C2 (ru) * 2014-06-06 2016-11-27 Олег Ильич Эпштейн Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
MXPA02010374A (es) * 1996-10-10 2003-04-25 Probe Internat Composiciones y metodos para tratar infecciones virales.
WO2001016182A2 (en) * 1999-08-27 2001-03-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
JPWO2004002511A1 (ja) * 2002-06-28 2005-10-27 扶桑薬品工業株式会社 抗ｈｉｖ剤
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
CN101152574A (zh) * 2002-09-27 2008-04-02 唐纳士公司 用于预防和治疗获得性免疫缺陷综合症的协同组合物
CA2518965C (en) 2003-03-14 2018-10-30 Nutrition Research Inc. Homeopathic formulations useful for treating pain and/or inflammmation
RU2393873C2 (ru) * 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
RU2315058C1 (ru) * 2006-09-27 2008-01-20 Институт органической химии Уфимского научного центра РАН Гликопептид глицирризиновой кислоты с глицил-l-фенилаланином, проявляющий анти-вич-1 активность
US20120263725A1 (en) * 2010-08-06 2012-10-18 Epshtein Oleg Iiiich Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV

Also Published As

Publication number Publication date
US20120263726A1 (en) 2012-10-18
DE112011102639T5 (de) 2013-10-02
SG187735A1 (en) 2013-03-28
RU2010133046A (ru) 2012-02-20
ES2415029A2 (es) 2013-07-23
ES2415029R1 (es) 2013-09-17
RU2517084C2 (ru) 2014-05-27
US20130315964A1 (en) 2013-11-28
PH12013500233A1 (en) 2017-08-23
ES2415029A8 (es) 2013-09-16
WO2012017322A3 (en) 2012-04-19
EA029791B1 (ru) 2018-05-31
GB201303865D0 (en) 2013-04-17
EA201300138A1 (ru) 2014-03-31
WO2012017322A2 (en) 2012-02-09
CA2807523A1 (en) 2012-02-09
JP2013535483A (ja) 2013-09-12
MX2013001450A (es) 2013-10-25
AU2011287286A1 (en) 2013-03-14
GB2496356A (en) 2013-05-08
CN103179987A (zh) 2013-06-26
UA112752C2 (uk) 2016-10-25

Similar Documents

Publication Publication Date Title
ITTO20110636A1 (it) Composizione farmaceutica e metodo per inibire la produzione o amplificare l'eliminazione della proteina p24
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
CY1119143T1 (el) Διεργασια για την παρασκευη παραγωγων και ενδιαμεσων καρβαμουλοπυριδονης
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
MA34091B1 (fr) Anticorps anti-cd40
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
FR2883179B1 (fr) Comprime enrobe
MX2013009151A (es) Inmunoterapia mejorada.
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
FR2897063B1 (fr) Polypeptides reconnus par des anticorps anti-trichinella, et leurs applications.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3